We describe a method for neonatal screening for biotinidase (EC 3.5.1.12) deficiency. Biotinidase activity is assessed colorimetrically from dried samples of whole blood spotted on the same filter papers as used inthe neonatal screening for phenylketonuria. After the reaction, samples from normal infants are characteristically purple, whereas those from affected individuals are straw-colored. To confirm the deficiency, the enzyme is quantitatively assayed in additional blood spots or serum. A pilot study has been initiated with samples obtained by the Commonwealth of Virginia for phenylketonuria testing We have recently shown (4) that the primary biochemical defect in LMCD is deficient activity of the enzyme biotinidase (biotin-amide amidohydrolase, EC 3.5.1.12), which catalyzes the removal of covalently bound biotin during carboxylase degradation (5, 6) and thus plays an important role in the recycling of this vitamin.
Symptoms
usually first appear during the first several postnatal months, but may not occur for several years.
Patients with the disorder may exhibit ketolactic acidosis and organic acidemia, caused by deficient activities of the biotin-dependent enzymes propionyl CoA carboxylase (EC 4.6.1.3), pyruvate carboxylase (EC 4.6.1.1), and /3-methylcrotonyl CoA carboxylase (EC 4.6.1.4) (2). These biochemical abnormalities can result in irreversible neurological damage or death. However, there is considerable clinical variability among patients from different families and among affected members of the same family (3). We have recently shown (4) that the primary biochemical defect in LMCD is deficient activity of the enzyme biotinidase (biotin-amide amidohydrolase, EC 3.5.1.12), which catalyzes the removal of covalently bound biotin during carboxylase degradation (5, 6) and thus plays an important role in the recycling of this vitamin.
The activity of the enzyme in the sera of patients with LMCD is almost undetectable (4).
In normal subjects biotinidase recycles biotin, whereas in biotinidase-deficient patients the biotin-salvage pathway is blocked, and high concentrations of dietary biotin are thus required to prevent or alleviate the symptoms of biotin deficiency (4). However, because the neurological and cutaneous manifestations of LMCD can occur in the absence of metabolic decompensation, there has usually been no reason to suspect the diagnosis at an early stage of the disease, nor could the diagnosis be confirmed without overt carboxylase deficiency (3). Consequently, the treatment of affected individuals was frequently not begun until irreparable damage had already occurred. Clearly, biotinidase deficiency satisfies several important criteria for neonatal screening: the worldwide, the actual incidence of the disorder is unknown. The lack of consanguinity in previously reported families and the great variability in the clinical expression of the disease suggest that the gene frequency may well be similar to or greater than those of other genetic disorders of metabolism for which screening is currently performed (7) . Moreover, as with phenylketonuria, the successful treatment of affected females may ultimately place their own offspring at risk of exposure to an unfavorable prenatal environment. At present, however, we believe this theoretical risk would be completely obviated by the continued treatment of such women with biotin throughout their lives and particularly during pregnancy. The purpose of our paper is to meet a final criterion for screening, i.e., the description of a simple, rapid diagnostic test for biotinidase deficiency; the same dried, blood-saturated paper discs currently used in most neonatal screening programs are utilined.
Materials and Methods

Sampling.
Dried, blood-saturated, punched filter-paper discs (3 mm diameter) were obtained from screening cards (Schleicher and Schuell, Inc., Keene, NH 03431) used by the Commonwealth of Virginia for phenylketonuria testing.
Apparatus.
The discs were automatically dropped by a Punch Indexer ( 
Reagents.
N-Biotinyl-p-aminobenzoate (B-PAB) was prepared as previously described (4) . N-1-Naphthylethylenediamine dihydrochloride, ammonium sulfamate, and paininobenzoic acid were obtained from J. T. Baker Chemical Co., Phillipsburg, NJ 08865; sodium nitrite from Eastman Kodak Co. Rochester, NY 14650; and trichloroacetic acid and potassium phosphate from Sigma Chemical Co., St.
Louis, MO 63178.We tested the following drugs for interfer- sample cup. The reaction trays were covered and incubated in a humidified chamber at 37 #{176}C. 
Results and Discussion
Incubation, development, and evaluation.
From a 24-h
time-course study ( Figure 1 ) we determined that incubation should last at least 4 h. For routine determinations we used a 16-h period (overnight), but 8-h incubation also allows the detection of affected individuals. Trays should be read within 30 mm of development, but the color is stable for at least2 h. Sample stability. Blood-saturated screening cards containing blood from normal and affected children were stored at room temperature and analyzed one, 30, and 60 days after collection.
Test cards that had been stored for as long as 3.5 years were also obtained from the neonatal screening program of the Commonwealth of Virginia. Normal samples storedfor no longer than 18 months still contained detectable biotinidase activity, whereas older samples and samples from affected infants did not. Routinely, samples can be tested anytime within seven days of collection. Consequently, and because the requirement of the screening procedure is for qualitative rather than quantitative assessment, slight losses of activity during storage will not alter the effectiveness of the method. on the presence of a free primary aromatic amino group, or one that can be freed by hydrolysis (9). Therapeutic drugs administered to the mother immediately before parturition, or to the infant, might interfere by contributing to color formation; the former situation has not been encountered, however. In the developmental stages of this program, a sample of serum from a five-year-old child known to have biotinidase deficiency turned intensely purple, well above the upper limit of normal samples, suggesting the presence of biotinidase activity. The serum alone, without incubation with substrate, also turned purple during the development treatment. Subsequent inquiries revealed that the child was being treated for an ear infection with a sulfonamide that contained a primary aromatic amino group.
Interference.
This colonmetric biotinidase assay depends
Two sulfonamides and other therapeutic drugs commonly used in the pennatal period were tested for their effect on color development. Predictably, the sulfonamides sulfisoxarole and a preparation containing trimethoprim and sulfamethoxa.zole (pulverized and suspended in water) turned purple when developed in the absence of B-PAB (9). Phenytom, ampicillmn, gentamicin sulfate, vitamin K, penicillin G potassium, and kanamycin sulfate (each reconstituted according to manufacturers' recommendations and added to separate reagent tubes in aliquots of 100 L) gave no color when developed in the absence of substrate. None of these other compounds contributed to or detracted from color development when p-aminobenzoate was present. Because the concentrations of these medications greatly exceeded the expected concentrations in serum (10, 11), the possibility of interference is remote. Nevertheless, we recommend that infants whose samples turn either intensely purple or have little or no color be further investigated. If there is intense color, the serum sample should be developed in substratefree buffer; subsequent color development would indicate the presence of interfering compounds. A quantitative assay of serum from infants yielding no activity in the screening test confirms the absence of activity; quantification of such samples will indicate the degree of enzyme deficiency.
Eight individuals referred to our laboratory have been diagnosed as having biotinidase deficiency (4).Although each had essentially undetectable biotinidase activity, we suspect that partial deficiencies may exist and could be missed by this method. We have also developed a radioisotopic assay for biotinidase (12), which has improved sensitivity and specificity. Compounds that interfere with the colorimetric assay do not affect this radioassay; this method can also be used to measure activity in samples from patients with putative biotinidase deficiency. The extra stepsand expense involved, however, preclude the use of the radioisotopic assay for routine screening. Cost-effectiveness. The incidence of biotinidase deficiency is unknown. However, in addition to the newly diagnosed individuals with biotinidase deficiency, several of the patients previously reported with LMCD have been shown to be biotinidase-deficient (K. Bartlett, J. M. Saudubray, and R. Baumgartner, personal communications). Most, if not all, patients with LMCD may be found to have biotinidase deficiency. Although some biotinidase-deficient patients exhibit organic aciduria and ketoacidosis, the disorder may occur without these symptoms. Because biotimdase deficiency is readily treatable, early identification of affected infants should enable the prompt initiation of biotin therapy. Excluding technical or administrative costs, we estimate that screening for this disorder would be extremely cost-effective, currently costing only $0.01 to $0.02 per test. A pilot study with samples obtained by the Commonwealth of Virginia for phenylketonuria testing has been initiated to determine the incidence of the disorder.
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